The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adults.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback